Welcome to Partnering with AstraZeneca
Improving health is one of the toughest challenges facing society today. As a global pure-play biopharmaceutical company, AstraZeneca has a key contribution to make by providing innovative medicines for some of the world’s most serious diseases.
We have a well defined business development strategy which is focused on supplementing the discovery, development and commercialisation of innovative medicines in our core therapy areas and complementing our technology capabilities through partnerships.
Why partnering is important to us
Partnering is an important supporting pillar of the overall strategy to supplement and strengthen our core pipeline and our position as a scientific leader.
The philosophy that ‘health connects us all’ drives our collaborative culture and approximately 40% of our overall pipeline has been sourced through partnerships.
BIO 2013 show reel
Watch some of the highlights from AstraZeneca's attendance at the 2013 BIO Convention in Chicago, US.
What we offer partners
Our goal is to offer our partners world class capabilities to bring new medicines to the market with a biotech mindset which encompasses quick, flexible, and creative decision making.
Our partnering process
We are committed to working with our collaborators to create tailored partnerships that are structured to best achieve our mutual goals.
Our areas of interest
Our partnering areas of interest are predominantly focused on three core disease areas which include cardiovascular & metabolic disease, respiratory, inflammation & autoimmune disease, and oncology. We remain interested but more opportunistic in partnering in the areas of infection and neuroscience. In addition we are interested in actively seeking collaborations in personalised healthcare and biomarkers, and around innovative science and technology platforms.
Talk to us
If you would like to begin a discussion about partnering, we look forward to talking and starting the process